Covered recipient · General Payments record
GEORGE CARR
Allopathic & Osteopathic Physicians Family Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$4,622.57
191 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $3,039.41 | 177 |
| Travel and Lodging | $1,562.94 | 13 |
| Education | $20.22 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Medtronic, Inc. | $1,963.16 | 26 |
| ABBVIE INC. | $484.31 | 31 |
| PFIZER INC. | $393.33 | 30 |
| AstraZeneca Pharmaceuticals LP | $336.99 | 16 |
| Novo Nordisk Inc | $259.57 | 18 |
| Bayer Healthcare Pharmaceuticals Inc. | $191.44 | 13 |
| Amgen Inc. | $182.95 | 13 |
| Lilly USA, LLC | $112.16 | 7 |
| Averitas Pharma Inc. | $103.54 | 5 |
| Dexcom, Inc. | $74.03 | 3 |
| Otsuka America Pharmaceutical, Inc. | $66.97 | 3 |
| GlaxoSmithKline, LLC. | $59.46 | 4 |
| Phathom Pharmaceuticals, Inc. | $47.14 | 3 |
| Tolmar, Inc. | $46.19 | 2 |
| Alkermes, Inc. | $39.07 | 2 |
| Exact Sciences Corporation | $33.98 | 2 |
| Lundbeck LLC | $31.76 | 2 |
| Abbott Laboratories | $31.73 | 2 |
| Ardelyx, Inc. | $29.94 | 2 |
| Esperion Therapeutics, Inc. | $29.34 | 1 |
| SK Life Science, Inc. | $21.64 | 1 |
| Antares Pharma, Inc. | $20.27 | 1 |
| Pharmacosmos Therapeutics Inc. | $17.31 | 1 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.67 | 1 |
| Sumitomo Pharma America, Inc. | $15.73 | 1 |
| Teva Pharmaceuticals USA, Inc. | $13.89 | 1 |
Page 4 of 4; records 151–191 of 191 matching records. This page contains 41 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
GEORGE CARR
NPI 1528032661 · CMS profile ID 114290
Allopathic & Osteopathic Physicians / Family Medicine
JEFFERSON CITY, MO
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 4; records 151–191 of 191 matching records. This page contains 41 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1528032661?year=2024&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- GEORGE CARR, NPI 1528032661, CMS profile ID 114290. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–191 of 191 matching records. This page contains 41 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1528032661?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). GEORGE CARR, NPI 1528032661, CMS profile ID 114290. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–191 of 191 matching records. This page contains 41 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1528032661?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- GEORGE CARR, NPI 1528032661, CMS profile ID 114290, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–191 of 191 matching records. This page contains 41 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1528032661?year=2024&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
191 matching records · $4,622.57 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–191 of 191.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Alkermes, Inc. | $21.99 | 03/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120476453 | CMS |
| Amgen Inc. | $12.08 | 03/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111543385 | CMS |
| Lundbeck LLC | $16.11 | 03/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145902986 | CMS |
| GlaxoSmithKline, LLC. | $13.86 | 03/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116475822 | CMS |
| Novo Nordisk Inc | $17.09 | 03/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1096598360 | CMS |
| Amgen Inc. | $15.86 | 03/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117218504 | CMS |
| Amgen Inc. | $9.51 | 03/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117218502 | CMS |
| PFIZER INC. | $14.70 | 03/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131230498 | CMS |
| ABBVIE INC. | $1.41 | 03/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103419737 | CMS |
| ABBVIE INC. | $3.59 | 03/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103419739 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $16.95 | 03/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086120674 | CMS |
| ABBVIE INC. | $11.84 | 02/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103419735 | CMS |
| Lilly USA, LLC | $15.83 | 02/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135006331 | CMS |
| ABBVIE INC. | $23.97 | 02/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103419733 | CMS |
| ABBVIE INC. | $26.29 | 02/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103419731 | CMS |
| Novo Nordisk Inc | $13.87 | 02/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1097600162 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.58 | 02/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104750916 | CMS |
| PFIZER INC. | $2.13 | 02/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131404535 | CMS |
| Novo Nordisk Inc | $12.51 | 02/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1096709363 | CMS |
| Amgen Inc. | $15.46 | 02/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117218500 | CMS |
| PFIZER INC. | $12.40 | 02/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131397545 | CMS |
| ABBVIE INC. | $15.23 | 02/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103419729 | CMS |
| Novo Nordisk Inc | $10.48 | 02/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1096604779 | CMS |
| SK Life Science, Inc. | $21.64 | 02/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1154139328 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.06 | 02/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105871589 | CMS |
| PFIZER INC. | $12.72 | 02/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131404530 | CMS |
| AstraZeneca Pharmaceuticals LP | $84.98 | 01/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104274827 | CMS |
| Lilly USA, LLC | $14.11 | 01/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1134987280 | CMS |
| Novo Nordisk Inc | $16.68 | 01/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1097273314 | CMS |
| ABBVIE INC. | $11.50 | 01/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103419727 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.15 | 01/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105780026 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $16.72 | 01/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086176966 | CMS |
| PFIZER INC. | $10.67 | 01/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131404522 | CMS |
| PFIZER INC. | $0.88 | 01/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131549605 | CMS |
| PFIZER INC. | $11.27 | 01/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131404192 | CMS |
| Alkermes, Inc. | $17.08 | 01/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120476451 | CMS |
| PFIZER INC. | $11.34 | 01/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131404526 | CMS |
| ABBVIE INC. | $23.35 | 01/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103419725 | CMS |
| GlaxoSmithKline, LLC. | $14.02 | 01/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116700391 | CMS |
| Abbott Laboratories | $17.23 | 01/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1125108372 | CMS |
| Otsuka America Pharmaceutical, Inc. | $18.22 | 01/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118871950 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $266,053.39 | 36 |
| PY2024 | Principal investigator | $282,417.33 | 368 |
| PY2023 | Principal investigator | $603,290.20 | 490 |
| PY2022 | Principal investigator | $514,463.11 | 368 |
| PY2021 | Principal investigator | $161,459.81 | 90 |
| PY2020 | Principal investigator | $20,469.56 | 2 |
| PY2019 | Principal investigator | $194,346.23 | 3 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
36 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $99.90 | 12/17/2025 | Non-covered Recipient Entity Jefferson City Medical Group Admin Office | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220692931 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1,669.24 | 12/12/2025 | Non-covered Recipient Entity Jefferson City Medical Group Admin Office | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220996494 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Jefferson City Medical Group Admin Office | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220692927 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1,669.24 | 11/07/2025 | Non-covered Recipient Entity Jefferson City Medical Group Admin Office | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220996492 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $27,382.36 | 11/05/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event | No dispute reported | 06/30/2026 | 1185546195 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Jefferson City Medical Group Admin Office | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220692925 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 10/27/2025 | Non-covered Recipient Entity Jefferson City Medical Group Admin Office | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220692929 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $6,676.96 | 10/08/2025 | Non-covered Recipient Entity Jefferson City Medical Group Admin Office | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220996490 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $123,245.53 | 10/06/2025 | Non-covered Recipient Entity JEFFERSON CITY MEDICAL GROUP, PC | A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients | No dispute reported | 06/30/2026 | 1190303687 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Jefferson City Medical Group Admin Office | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220692923 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $6,676.96 | 09/26/2025 | Non-covered Recipient Entity Jefferson City Medical Group Admin Office | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220996488 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $391.52 | 09/22/2025 | Non-covered Recipient Entity Jefferson City Medical Group Admin Office | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220802394 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17,700.00 | 09/22/2025 | Non-covered Recipient Entity Qcare Site Services, Inc Avacare | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220812988 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Jefferson City Medical Group Admin Office | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220692917 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $259.74 | 08/26/2025 | Non-covered Recipient Entity Jefferson City Medical Group Admin Office | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220692919 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 08/26/2025 | Non-covered Recipient Entity Jefferson City Medical Group Admin Office | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220692921 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.75 | 08/01/2025 | Non-covered Recipient Entity Jefferson City Medical Group Admin Office | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220692909 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 08/01/2025 | Non-covered Recipient Entity Jefferson City Medical Group Admin Office | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220692911 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 08/01/2025 | Non-covered Recipient Entity Jefferson City Medical Group Admin Office | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220692913 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity Jefferson City Medical Group Admin Office | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220692915 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $44,127.07 | 07/23/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event | No dispute reported | 06/30/2026 | 1185546198 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,687.00 | 07/14/2025 | Non-covered Recipient Entity Jefferson City Medical Group | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215517366 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,500.00 | 07/14/2025 | Non-covered Recipient Entity Jefferson City Medical Group | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215517369 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,895.00 | 07/14/2025 | Non-covered Recipient Entity Jefferson City Medical Group | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215517373 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,200.00 | 07/14/2025 | Non-covered Recipient Entity Jefferson City Medical Group | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215517378 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,500.00 | 07/02/2025 | Non-covered Recipient Entity Jefferson City Medical Group | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215517351 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,520.00 | 07/02/2025 | Non-covered Recipient Entity Jefferson City Medical Group | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215517357 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,066.00 | 07/02/2025 | Non-covered Recipient Entity Jefferson City Medical Group | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215517362 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,500.00 | 07/02/2025 | Non-covered Recipient Entity Jefferson City Medical Group | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215517382 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $6,500.00 | 07/02/2025 | Non-covered Recipient Entity JEFFERSON CITY MEDICAL GROUP, PC | a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older | No dispute reported | 06/30/2026 | 1185546201 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,059.22 | 05/12/2025 | Non-covered Recipient Entity JEFFERSON CITY MEDICAL GROUP | A PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED, MULTI-COUNTRY STUDY TO EVAL | No dispute reported | 06/30/2026 | 1192138652 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $17.00 | 02/28/2025 | Non-covered Recipient Entity Jefferson City Medical Group | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215517343 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/28/2025 | Non-covered Recipient Entity Jefferson City Medical Group | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215517347 |
| Principal investigator 1 | AstraZeneca UK Limited | $16,039.00 | 02/21/2025 | Non-covered Recipient Entity JEFFERSON CITY MEDICAL GROUP, PC | A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment | No dispute reported | 06/30/2026 | 1185546193 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2025 | Non-covered Recipient Entity Jefferson City Medical Group | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215517336 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $17.00 | 01/31/2025 | Non-covered Recipient Entity Jefferson City Medical Group | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215517339 |